Market Overview

UPDATE: Benchmark Raises PT to $20 on Exact Sciences Corporation Ahead of Top Line Data

Share:
Related EXAS
Analyst Leaves Exact Sciences CEO Meeting With 'Fortified Confidence' Despite Recent Controversy
The Market In 5 Minutes
The Vetr community has downgraded $EXAS to 4-Stars (Vetr)

Benchmark maintained Exact Sciences Corporation (NASDAQ: EXAS) with a Speculative Buy and raised the price target from $17.00 to $20.00.

Benchmnark noted, "Exact's Q4 update affirmed our expectation that pivotal top line colorectal cancer study data should be announced in March or April. These results are expected to support the third and final modular PMA filing seeking approval of a colon cancer and pre-cancer screening test. Based on prior tests demonstrating up to 98% cancer sensitivity, we believe there is a high likelihood this prospective study can demonstrate cancer sensitivity that exceeds the FDA's anticipated 85% threshold for approval."

Exact Sciences Corporation closed at $10.56 on Wednesday.

Latest Ratings for EXAS

DateFirmActionFromTo
Apr 2017Cowen & Co.MaintainsOutperformOutperform
Mar 2017Cowen & Co.Initiates Coverage OnOutperform
Feb 2017Roth CapitalUpgradesNeutralBuy

View More Analyst Ratings for EXAS
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Price Target Analyst Ratings

 

Related Articles (EXAS)

View Comments and Join the Discussion!